Novel needle-free Intradermal (ID) delivery technologies provide effective alternatives to traditional Mantoux ID administration using needles. An in-depth review of 59 published scientific ...
PharmaJet will deliver two presentations on October 27 focusing on current and future applications of their needle-free technology. The Tropis ® intradermal (ID) Needle-free Injection System overcomes ...
PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (OTCBB: BJCT), a leading developer of needle-free injection therapy systems, today announced that Bioject’s needle-free injection ...
PharmaJet presentation will highlight the results of recent immunization studies using needle-free intradermal (ID) delivery for polio immunization campaigns. Data reinforces how increased coverage, ...
The MarketWatch News Department was not involved in the creation of this content. -- Single-use and reusable needle-free injection devices will be designed for precise self-administration and home use ...
The global intradermal injection market size is expected to surpass an impressive valuation of USD 3,878 Million in 2022 and is projected to exhibit a compound annual growth rate (CAGR) of 10.8% from ...
The Tropis ® intradermal (ID) Needle-free Injection System overcomes the challenges of traditional Mantoux injection and can easily be integrated into commercial products and development projects.
(BUSINESS WIRE )-- PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that they will share the latest routine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results